

Rosalinda Allegro

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6159405/rosalinda-allegro-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26

papers

253

citations

10

h-index

15

g-index

50

ext. papers

302

ext. citations

2.1

avg, IF

1.96

L-index

#	Paper	IF	Citations
26	Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. <i>Urology</i> , 2005 , 65, 65-9	1.6	36
25	Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). <i>Prostate</i> , 2014 , 74, 1471-80	4.2	32
24	PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2008 , 11, 148-52	6.2	28
23	TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years. <i>European Urology</i> , 2004 , 45, 730-5; discussion 735-6	10.2	28
22	A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. <i>BJU International</i> , 2010 , 106, 212-7	5.6	21
21	Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder. A study from Gruppo Studi Tumori Urologici Foundation. <i>Urologia Internationalis</i> , 2006 , 77, 152-8	1.9	16
20	Prediction by quantitative histology of pathological stage in prostate cancer. <i>European Journal of Surgical Oncology</i> , 2005 , 31, 309-13	3.6	15
19	Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma. <i>Urology</i> , 2013 , 81, 277-81	1.6	14
18	A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 174-9	3.3	14
17	Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e751-e758	3.3	10
16	Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2003 , 129, 472-6	4.9	8
15	Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumors selected for conservative treatment. <i>Journal of Urology</i> , 2008 , 180, 886-90; discussion 891	2.5	7
14	Cigarette smoking and drinking water source: correlation with clinical features and pathology of superficial bladder carcinoma. <i>Urologia Internationalis</i> , 2009 , 82, 318-23	1.9	5
13	Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital. <i>Urologia Internationalis</i> , 2009 , 83, 452-7	1.9	5
12	Is free/total PSA predictive of pathological stage and Gleason score in patients with prostate cancer and serum PSA. <i>Urologia Internationalis</i> , 2006 , 76, 232-5	1.9	3
11	Prevention of topic toxicity of BCG with single-dose prulifloxacin. Preliminary results of a randomized pilot study. <i>Urologia</i> , 2010 , 77, 240-247	1.2	2
10	Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study. <i>BJU International</i> , 2003 , 92, 545-49; discussion 549-50	5.6	2

9	Is PSA density still useful in diagnosing prostate cancer?. <i>Archivio Italiano Di Urologia Andrologia</i> , 2009 , 81, 199-202	1.6	2
8	Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy. <i>Urology Annals</i> , 2015 , 7, 21-5	1	1
7	The assessment of the attitude of Sicilian consumers towards wild and farmed seafood products: a sample survey. <i>British Food Journal</i> , 2021 , 123, 2506-2536	2.8	1
6	Risk Assessment of Cadmium, Lead, and Mercury on Human Health in Relation to the Consumption of Farmed Sea Bass in Italy: A Meta-Analytical Approach. <i>Frontiers in Marine Science</i> , 2021 , 8,	4.5	1
5	Validation of a Commercial Loop-Mediated Isothermal Amplification (LAMP)-Based Kit for the Detection of Salmonella spp. According to ISO 16140:2016. <i>Applied Sciences (Switzerland)</i> , 2021 , 11, 6669	2.6	0
4	The Multicriteria Electre III Model Applied to the Evaluation of the Placement of University Graduates. <i>Contributions To Statistics</i> , 2011 , 175-194	0.1	
3	Conservative Management and Survival of Patients Affected by T1G3 Bladder Tumours. When Shall we Indicate it and When the Cystectomy?. <i>Urologia</i> , 2009 , 76, 31-35	1.2	
2	Results at 48 Months of a Randomized Trial on Maintenance after Early Adjuvant. <i>Urologia</i> , 2009 , 76, 27-30	1.2	
1	Low-Risk Bladder Tumors: How Accurate are the EORTC Risk Tables?. <i>Urologia</i> , 2009 , 76, 36-38	1.2	